Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Table 1 Characteristics of patients at treatment initiation

	All patients (n = 104)	Hypothyroidism
		Yes (n = 21)	No (n = 83)	P value
Male/female	69/35	14/7	55/28	1.000
Median age (min-max) (years)	68.5 (32-91)	70.0 (45-91)	68.0 (32-88)	0.382
Body weight (kg)	52.7 ± 11.9	54.0 ± 9.6	52.4 ± 12.4	0.340
Cancer type
Head and neck cancer	29	6	23	1.000
Non-small-cell lung cancer	29	6	23	1.000
Malignant melanoma	16	1	15	0.183
Renal cell cancer	15	4	11	0.497
Gastric cancer	15	4	11	0.497
Laboratory data
TSH (µIU/mL)	2.08 ± 0.80	2.34 ± 0.78	2.02 ± 0.79	0.058
FT3 (pg/mL)	2.21 ± 0.50	2.12 ± 0.32	2.23 ± 0.54	0.584
FT4 (ng/dL)	1.18 ± 0.20	1.11 ± 0.20	1.20 ± 0.19	0.064
NLR	4.17 ± 3.73	2.54 ± 1.21	4.58 ± 4.03	0.017
NLR < 3.5	60	16	44	0.082
NLR ≥ 3.5	44	5	39
NLR < 5	78	20	58	0.022
NLR ≥ 5	26	1	25

TSH: Thyroid-stimulating hormone; FT3: Free triiodothyronine; FT4: Free thyroxine; NLR: Neutrophil-to-lymphocyte ratio; min: Minimum; max: Maximum.